128 related articles for article (PubMed ID: 26141653)
1. A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits.
Nakamae H; Yoshida C; Miyata Y; Hidaka M; Uike N; Koga D; Sogabe T; Matsumura I; Kanakura Y; Naoe T
Int J Hematol; 2015 Sep; 102(3):304-11. PubMed ID: 26141653
[TBL] [Abstract][Full Text] [Related]
2. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K
Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508
[TBL] [Abstract][Full Text] [Related]
3. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale.
Furuya D; Moriai M; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S
Int J Clin Oncol; 2019 Jul; 24(7):871-875. PubMed ID: 30798394
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution.
Ribeiro BF; Vergílio BR; Miranda EC; Almeida MH; Delamain MT; da Silveira RA; de Souza CA; Albuquerque DM; Santos AD; Duarte VO; Oliveira-Duarte GB; Lorand-Metze I; Pagnano KB
Acta Haematol; 2015; 134(4):248-54. PubMed ID: 26159458
[TBL] [Abstract][Full Text] [Related]
5. [Significance of quantitative detection of bcr-abl mRNA in chronic myeloid leukemia patients after allogeneic hematopoietic stem cell transplant].
Geng SX; DU X; Weng JY; Li QH; Su JH; Lin QX; Li YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):993-7. PubMed ID: 17956677
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients.
le Coutre P; Reinke P; Neuhaus R; Trappe R; Ringel F; Lalancette M; Hemmati PG; Dörken B; Daniel PT
Eur J Haematol; 2010 Jan; 84(1):26-33. PubMed ID: 19799626
[TBL] [Abstract][Full Text] [Related]
7. Negative MR
Cerveira N; Diamond J; Matos S; Amorim ML; Coucelo M; Bizarro S; Simões AT; Pierdomenico F; Lopes M; Ribeiro L; do Carmo-Fonseca M; Guimarães JE; Almeida A; Teixeira MR
Br J Haematol; 2019 Sep; 186(6):e181-e184. PubMed ID: 31218669
[No Abstract] [Full Text] [Related]
8. Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
Koren-Michowitz M; Shimoni A; Daraio F; Crasto F; Lorenzatti R; Volchek Y; Amariglio N; Gottardi E; Saglio G; Nagler A
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1852-5. PubMed ID: 26151304
[TBL] [Abstract][Full Text] [Related]
9. Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay.
Chung HJ; Hur M; Yoon S; Hwang K; Lim HS; Kim H; Moon HW; Yun YM
Ann Lab Med; 2020 Jan; 40(1):72-75. PubMed ID: 31432643
[TBL] [Abstract][Full Text] [Related]
10. Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization.
Müller MC; Merx K; Weisser A; Kreil S; Lahaye T; Hehlmann R; Hochhaus A
Leukemia; 2002 Dec; 16(12):2395-9. PubMed ID: 12454744
[TBL] [Abstract][Full Text] [Related]
11. Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients.
Moumen A; Dehbi H; Kottwitz D; El Amrani M; Bouchoutrouch N; El Hadi H; Quessar A; Benchekroun S; Nadifi S; Sefrioui H
Genet Mol Res; 2015 Feb; 14(1):1044-55. PubMed ID: 25730044
[TBL] [Abstract][Full Text] [Related]
12. The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.
Jiang Q; Zhao XY; Qin YZ; Liu YR; Lai YY; Jiang B; Huang XJ
Am J Hematol; 2012 Dec; 87(12):1065-9. PubMed ID: 22965919
[TBL] [Abstract][Full Text] [Related]
13. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
14. Minimal Residual Disease Eradication in CML: Does It Really Matter?
Tantravahi SK; Guthula RS; O'Hare T; Deininger MW
Curr Hematol Malig Rep; 2017 Oct; 12(5):495-505. PubMed ID: 28852963
[TBL] [Abstract][Full Text] [Related]
15. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
16. Detection of bcr/abl mRNA in a case of chronic myelogenous leukemia in long-term remission: CML or sensitivity of detection?
Anguita E; Villegas A; Díaz-Mediavilla J; González FA; del Potro E; Espinós D
Haematologica; 1998 Aug; 83(8):744-7. PubMed ID: 9793259
[TBL] [Abstract][Full Text] [Related]
17. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
[TBL] [Abstract][Full Text] [Related]
18. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
19. Quantification of BCR-ABL mRNA in plasma/serum of patients with chronic myelogenous leukemia.
Narita M; Saito A; Kojima A; Iwabuchi M; Satoh N; Uchiyama T; Yamahira A; Furukawa T; Sone H; Takahashi M
Int J Med Sci; 2012; 9(10):901-8. PubMed ID: 23155364
[TBL] [Abstract][Full Text] [Related]
20. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
